|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US5697901A
(en)
|
1989-12-14 |
1997-12-16 |
Elof Eriksson |
Gene delivery by microneedle injection
|
|
FI101678B
(fi)
|
1990-12-31 |
1998-08-14 |
Akzo Nv |
Happolabiileja kytkentämolekyylejä
|
|
AU664561B2
(en)
|
1991-06-21 |
1995-11-23 |
University Of Cincinnati, The |
Orally administrable therapeutic proteins and method of making
|
|
US6613332B1
(en)
|
1991-06-21 |
2003-09-02 |
The University Of Cincinnati |
Oral administration of therapeutic proteins
|
|
IL99120A0
(en)
|
1991-08-07 |
1992-07-15 |
Yeda Res & Dev |
Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
US5505931A
(en)
|
1993-03-04 |
1996-04-09 |
The Dow Chemical Company |
Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6261554B1
(en)
|
1995-07-25 |
2001-07-17 |
Introgene B.V. |
Compositions for targeted gene delivery
|
|
DE69733815T2
(de)
|
1996-02-15 |
2006-06-08 |
Biosense Webster, Inc., Diamond Bar |
Sonde zur exkavation
|
|
AU3739697A
(en)
|
1996-07-09 |
1998-02-02 |
Johns Hopkins University, The |
Gene delivery system
|
|
US6541615B1
(en)
|
1996-11-15 |
2003-04-01 |
Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. |
SIRP proteins and uses thereof
|
|
CA2226962A1
(en)
|
1998-02-16 |
1999-08-16 |
Marie Sarfati |
Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
|
|
AU5591200A
(en)
|
1999-06-11 |
2001-01-02 |
Human Genome Sciences, Inc. |
49 human secreted proteins
|
|
US6613026B1
(en)
|
1999-12-08 |
2003-09-02 |
Scimed Life Systems, Inc. |
Lateral needle-less injection apparatus and method
|
|
GB9930706D0
(en)
|
1999-12-24 |
2000-02-16 |
Medical Res Council |
Composition for inhibiting macrophage activity
|
|
US7662367B2
(en)
|
2000-03-02 |
2010-02-16 |
Xencor, Inc. |
Pharmaceutical compositions for the treatment of TNF-α related disorders
|
|
TWI327597B
(en)
|
2001-08-01 |
2010-07-21 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
|
GB0124145D0
(en)
|
2001-10-08 |
2001-11-28 |
Bayer Ag |
Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
|
|
CA2478047C
(en)
|
2002-03-01 |
2014-01-21 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
US20170281791A1
(en)
|
2002-03-01 |
2017-10-05 |
Immunomedics, Inc. |
Anti-trop-2 antibody-drug conjugates and uses thereof
|
|
US20040018522A1
(en)
|
2002-05-09 |
2004-01-29 |
Brigham And Women's Hospital, Inc. |
Identification of dysregulated genes in patients with multiple sclerosis
|
|
US7879544B2
(en)
|
2002-07-29 |
2011-02-01 |
Hmgene Inc. |
Methods of identifying adipocyte specific genes, the genes identified, and their uses
|
|
AU2003291625B2
(en)
|
2002-09-16 |
2009-10-08 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
NZ540194A
(en)
|
2002-11-08 |
2008-07-31 |
Ablynx Nv |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
US20100215640A1
(en)
|
2003-04-24 |
2010-08-26 |
The University Of North Carolina At Chapel Hill |
Method for inhibiting cellular activation by insulin-like growth factor-1
|
|
US8613922B2
(en)
|
2003-04-24 |
2013-12-24 |
The University Of North Carolina At Chapel Hill |
Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
|
|
US20040213792A1
(en)
|
2003-04-24 |
2004-10-28 |
Clemmons David R. |
Method for inhibiting cellular activation by insulin-like growth factor-1
|
|
US7691970B2
(en)
|
2003-08-25 |
2010-04-06 |
Pieris Ag |
Muteins of a bilin-binding protein with affinity for a given target
|
|
WO2005084198A2
(en)
|
2004-02-27 |
2005-09-15 |
Vaxconsulting |
Peptides of il1 beta and tnf alpha and method of treatment using same
|
|
EP1737480A2
(de)
|
2004-03-29 |
2007-01-03 |
Seth Hallström |
Pharmazeutisches kombinationspr parat enthaltend ein therape utisches protein
|
|
US20080299042A1
(en)
|
2004-04-30 |
2008-12-04 |
Biogen Idec Ma Inc. |
Membrane Associated Molecules
|
|
US7514229B2
(en)
|
2005-09-29 |
2009-04-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for diagnosing and evaluating treatment of blood disorders
|
|
AR060017A1
(es)
|
2006-01-13 |
2008-05-21 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos de dickkopf -1
|
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
US20090068195A1
(en)
|
2007-04-23 |
2009-03-12 |
Wyeth |
Methods and compositions for treating and monitoring treatment of il-13-associated disorders
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
JP2011500005A
(ja)
|
2007-10-11 |
2011-01-06 |
ユニバーシティー ヘルス ネットワーク |
ヒト造血幹細胞の生着を増加させるためのSIRPα−CD47相互作用の調節およびそのための化合物
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
PT3056515T
(pt)
|
2008-01-15 |
2019-07-19 |
Univ Leland Stanford Junior |
Métodos para manipulação da fagocitose mediada por cd47
|
|
EP2111869A1
(en)
|
2008-04-23 |
2009-10-28 |
Stichting Sanquin Bloedvoorziening |
Compositions and methods to enhance the immune system
|
|
BRPI0923442A2
(pt)
|
2008-12-19 |
2016-01-12 |
Novartis Ag |
polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
DK2429574T3
(da)
|
2009-05-15 |
2015-06-22 |
Univ Health Network |
Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
|
|
EP2456454A4
(en)
|
2009-07-20 |
2013-03-20 |
Univ Nat Cheng Kung |
FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
|
|
KR101632312B1
(ko)
|
2009-11-03 |
2016-06-21 |
삼성전자주식회사 |
항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
|
|
CN102711810B
(zh)
|
2009-11-30 |
2015-04-22 |
詹森生物科技公司 |
效应子功能已消除的抗体Fc区突变体
|
|
KR20120107122A
(ko)
|
2009-12-22 |
2012-09-28 |
노파르티스 아게 |
치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
|
|
AU2011252851B2
(en)
|
2010-05-14 |
2016-10-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to CD47
|
|
CA2814040C
(en)
|
2010-10-08 |
2021-03-23 |
Joshua Michael Donaldson |
A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
|
|
US8609621B2
(en)
|
2010-11-15 |
2013-12-17 |
E I Du Pont De Nemours And Company |
Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
|
|
US9566347B2
(en)
|
2011-02-07 |
2017-02-14 |
The Trustees Of The University Of Pennsylvania |
Peptides and methods using same
|
|
LT2691417T
(lt)
|
2011-03-29 |
2018-10-25 |
Roche Glycart Ag |
Antikūno fc variantai
|
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
BR112013027224A8
(pt)
|
2011-04-22 |
2018-08-14 |
Emergent Product Dev Seattle |
Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
|
|
MX2013014789A
(es)
|
2011-06-16 |
2014-01-20 |
Novartis Ag |
Proteinas solubles para utilizarse como productos terapeuticos.
|
|
WO2013056352A1
(en)
|
2011-10-19 |
2013-04-25 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
|
WO2013063076A1
(en)
|
2011-10-25 |
2013-05-02 |
Indiana University Research & Technology Corporation |
Compositions for and methods of modulating complications, risks and issues with xenotransplantation
|
|
EP3766511A1
(en)
|
2012-01-17 |
2021-01-20 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity sirp-alpha reagents
|
|
US9428553B2
(en)
|
2012-02-10 |
2016-08-30 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
|
SG11201408554QA
(en)
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
GB201216649D0
(en)
|
2012-09-18 |
2012-10-31 |
Univ Birmingham |
Agents and methods
|
|
ME03550B
(me)
|
2012-12-17 |
2020-07-20 |
Trillium Therapeutics Inc |
Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama
|
|
WO2014121093A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Fusion proteins that facilitate cancer cell destruction
|
|
EP3311824B1
(en)
|
2013-02-05 |
2020-03-25 |
The Board of Trustees of the Leland Stanford Junior University |
Cd47 targeted therapies for the treatment of infectious disease
|
|
CA2905418C
(en)
|
2013-03-13 |
2023-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
CN105189556A
(zh)
|
2013-03-15 |
2015-12-23 |
小利兰·斯坦福大学托管委员会 |
用于实现治疗有效剂量的抗cd47剂的方法
|
|
WO2014179132A1
(en)
|
2013-04-29 |
2014-11-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Use of anti-cd47 agents to enhance immunization
|
|
US9945870B2
(en)
|
2013-05-17 |
2018-04-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for determining responsiveness to an anti-CD47 agent
|
|
EP3027647A4
(en)
|
2013-07-31 |
2017-01-04 |
Amgen Inc. |
Stabilization of fc-containing polypeptides
|
|
ES2765483T3
(es)
|
2013-09-18 |
2020-06-09 |
Univ Leland Stanford Junior |
Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
|
|
HRP20231121T1
(hr)
|
2013-09-23 |
2023-12-22 |
Regeneron Pharmaceuticals, Inc. |
Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale
|
|
KR20250051130A
(ko)
|
2013-09-25 |
2025-04-16 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
AU2014337367B2
(en)
|
2013-10-15 |
2020-04-30 |
The Scripps Research Institute |
Peptidic chimeric antigen receptor T cell switches and uses thereof
|
|
EP3628328B1
(en)
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
KR20200029627A
(ko)
|
2014-03-12 |
2020-03-18 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
EP3188758B1
(en)
|
2014-08-08 |
2023-10-04 |
The Board of Trustees of the Leland Stanford Junior University |
Sirp alpha-antibody fusion proteins
|
|
WO2016023040A1
(en)
|
2014-08-08 |
2016-02-11 |
Alexo Therapeutics International |
Sirp-alpha variant constructs and uses thereof
|
|
EP3177640B1
(en)
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
|
WO2016023001A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multispecific high affinity pd-1 agents and methods of use
|
|
ES2751915T5
(es)
|
2014-08-15 |
2022-12-23 |
Merck Patent Gmbh |
Proteínas de fusión de inmunoglobulina con SIRP alfa
|
|
ES2945588T3
(es)
|
2014-08-26 |
2023-07-04 |
Univ Leland Stanford Junior |
Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
|
|
US10822411B2
(en)
|
2014-09-15 |
2020-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
|
AU2015329696A1
(en)
|
2014-10-10 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting CD47
|
|
WO2016065329A1
(en)
|
2014-10-24 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
|
HUE054012T2
(hu)
|
2014-10-29 |
2021-08-30 |
Five Prime Therapeutics Inc |
Kombinációs terápia rák ellen
|
|
WO2016081423A1
(en)
|
2014-11-18 |
2016-05-26 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
|
ES2838925T3
(es)
|
2015-02-27 |
2021-07-02 |
Univ Leland Stanford Junior |
Terapia de combinación para el tratamiento de la ateroesclerosis
|
|
CN106146670B
(zh)
|
2015-04-24 |
2019-01-15 |
宜明昂科生物医药技术(上海)有限公司 |
一种新的重组双功能融合蛋白及其制备和应用
|
|
DK3298043T3
(da)
|
2015-05-18 |
2021-02-15 |
Ab Initio Biotherapeutics Inc |
SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
|
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
|
RU2740672C2
(ru)
|
2015-08-07 |
2021-01-19 |
ЭйЭлЭкс Онколоджи Инк. |
Конструкции, имеющие sirp-альфа домен или его вариант
|
|
ES2894335T5
(es)
|
2015-08-26 |
2024-06-27 |
Univ Leland Stanford Junior |
Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
|
|
DK4186927T3
(da)
|
2015-10-21 |
2025-06-10 |
Ose Immunotherapeutics |
Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft
|
|
US10613092B2
(en)
|
2016-04-01 |
2020-04-07 |
Agilent Technologies, Inc. |
Scoring methods for anti-PD therapy eligibility and compositions for performing same
|
|
WO2017177333A1
(en)
|
2016-04-15 |
2017-10-19 |
Trillium Therapeutics Inc. |
Macrophage stimulation in cd47 blockade therapy
|
|
EP3493845A4
(en)
|
2016-08-03 |
2020-04-15 |
The Board of Trustees of the Leland Stanford Junior University |
INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
KR102804118B1
(ko)
|
2016-10-06 |
2025-05-09 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
WO2018081898A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
CA3042581A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
CN110325549B
(zh)
|
2016-12-09 |
2024-03-08 |
艾利妥 |
抗SIRPα抗体及其使用方法
|
|
CN110300764A
(zh)
|
2017-02-17 |
2019-10-01 |
Ose免疫疗法 |
抗SIRPg抗体的新用途
|
|
PT3443010T
(pt)
|
2017-02-17 |
2024-10-21 |
Ose Immunotherapeutics |
Novos anticorpos anti-sirpa e suas aplicações terapêuticas
|
|
CA3057718A1
(en)
|
2017-03-28 |
2018-10-04 |
Trillium Therapeutics Inc. |
Cd47 blockade therapy
|
|
JP7160833B2
(ja)
|
2017-04-13 |
2022-10-25 |
サイロパ ビー.ブイ. |
抗sirpアルファ抗体
|
|
PT3625259T
(pt)
|
2017-05-16 |
2024-07-04 |
Synthon Biopharmaceuticals Bv |
Anticorpos anti-sirpalfa
|
|
ES2976558T3
(es)
|
2017-06-21 |
2024-08-05 |
The Board Of Trustees Of The Leland Stanfordjunior Univ |
Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas
|
|
EP3658589B1
(en)
|
2017-07-26 |
2023-09-27 |
Forty Seven, Inc. |
Anti-sirp-alpha antibodies and related methods
|
|
JP2021534769A
(ja)
|
2018-08-31 |
2021-12-16 |
エーエルエックス オンコロジー インコーポレイテッド |
デコイポリペプチド
|
|
EP3980747A1
(en)
|
2019-06-07 |
2022-04-13 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
JP2023528341A
(ja)
|
2020-06-01 |
2023-07-04 |
エーエルエックス オンコロジー インコーポレイテッド |
低メチル化剤を含むがんを治療するための併用療法
|
|
WO2022010806A1
(en)
|
2020-07-06 |
2022-01-13 |
ALX Oncology Inc. |
Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
CA3253030A1
(en)
|
2022-06-01 |
2023-12-07 |
ALX Oncology Inc. |
Polytherapy for the treatment of urothelial carcinoma
|